Efficiency of CYP2C9 Genetic Test Representation for Automated Pharmacogenetic Decision Support

被引:12
|
作者
Deshmukh, V. G. [1 ]
Hoffman, M. A. [2 ]
Arnoldi, C. [2 ]
Bray, B. E. [1 ]
Mitchell, J. A. [1 ]
机构
[1] Univ Utah, Sch Med, Dept Biomed Informat, Salt Lake City, UT 84112 USA
[2] Cerner Corp, Kansas City, MO USA
关键词
Pharmacogenetics; clinical decision support systems; SNP; allele; CYTOCHROME-P450; CYP2C9; DOSE REQUIREMENT; WARFARIN; METABOLISM; GENOMICS; ANTICOAGULATION; THERAPY;
D O I
10.3414/ME0570
中图分类号
TP [自动化技术、计算机技术];
学科分类号
0812 ;
摘要
Objectives: We investigated the suitability of representing discrete genetic test results in the electronic health record (EHR) as individual single nucleotide polymorphisms (SNPs) and as alleles, using the CYP2C9 gene and its polymorphic states, as part of a pilot study. The purpose of our investigation was to determine the appropriate level of data abstraction when reporting genetic test results in the EHR that would allow meaningful interpretation and clinical decision support based on current knowledge, while retaining sufficient information in order to enable reinterpretation of the results in the context of future discoveries. Methods: Based on the SNP & allele models, we designed two separate lab panels within the laboratory information system, one containing SNPs and the other containing alleles, built separate rules in the clinical decision support system based on each model, and evaluated the performance of these rules in an EHR simulation environment using real-world scenarios. Results: Although decision-support rules based on allele model required significantly less computational time than rules based on SNP model, no difference was observed on the total time taken to chart medication orders between rules based on these two models. Conclusions: Both, SNP- and allele-based models, can be used effectively for representing genetic test results in the EHR without impacting clinical decision support systems. While storing and reporting genetic test results as alleles allow for the construction of simpler decision-support rules, and make it easier to present these results to clinicians, SNP-based model can retain a greater amount of information that could be useful for future reinterpretation.
引用
收藏
页码:282 / 290
页数:9
相关论文
共 50 条
  • [31] Identification and Functional Assessment of a New CYP2C9 Allelic Variant CYP2C9☆59
    Dai, Da-Peng
    Wang, Shuang-Hu
    Li, Chuan-Bao
    Geng, Pei-Wu
    Cai, Jie
    Wang, Hao
    Hu, Guo-Xin
    Cai, Jian-Ping
    DRUG METABOLISM AND DISPOSITION, 2015, 43 (08) : 1246 - 1249
  • [32] Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study
    Vicente, Jorge
    Gonzalez-Andrade, Fabricio
    Soriano, Antonia
    Fanlo, Ana
    Martinez-Jarreta, Begona
    Sinues, Blanca
    MOLECULAR BIOLOGY REPORTS, 2014, 41 (03) : 1267 - 1272
  • [33] Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy
    Muhammad, Sumaira Deen
    Khan, Hazar
    Hussain, Mushtaq
    Zeb, Tehseen Fatima
    Kumar, Darshan
    Rahi, Rahimullah
    Asif, Mahayrookh
    Balooch, Akhter Ali
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 33 (04) : 1771 - 1777
  • [34] Warfarin dose requirements in a patient with the CYP2C9*14 allele
    Lee, Yee Ming
    Eggen, Jessica
    Soni, Vinay
    Drozda, Katarzyna
    Nutescu, Edith A.
    Cavallari, Larisa H.
    PHARMACOGENOMICS, 2014, 15 (07) : 909 - 914
  • [35] Warfarin therapy in a patient homozygous for the CYP2C9*3 allele
    Ablin, J
    Cabili, S
    Lagziel, A
    Peretz, H
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2002, 4 (02): : 139 - 141
  • [36] CYP2C9 polymorphisms: Considerations in NSAID therapy
    Ali, Zaynah K.
    Kim, Rebekah J.
    Ysla, Francis M.
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2009, 12 (01) : 108 - 114
  • [37] Clinical relevance of genetic polymorphisms in the human CYP2C9 gene
    Schwarz, UI
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2003, 33 : 23 - 30
  • [38] Frequencies of CYP2C9 polymorphisms in a Syrian cohort
    Aldiban, Weam
    Aljamali, Majd N.
    Youssef, Lama A.
    BMC GENOMICS, 2025, 26 (01):
  • [39] Warfarin maintenance dose associated with genetic polymorphisms of CYP2C9
    Khaleqsefat, E.
    Khalaj-Kondori, M.
    Bonyadi, Jabbarpour M.
    Battaloglu, E.
    HIPPOKRATIA, 2017, 21 (02) : 93 - 96
  • [40] Pharmacogenetic variants of CYP2C9 and CYP2C19 associated with adverse reactions induced by antiepileptic drugs used in Peru
    Alvarado, Angel
    Munoz, Ana Maria
    Varela, Nelson
    Sullon-Dextre, Luis
    Pineda, Mario
    Bolarte-Arteaga, Mario
    Bendezu, Maria R.
    Garcia, Jorge A.
    Chavez, Haydee
    Surco-Laos, Felipe
    Melgar-Merino, Elizabeth J.
    Cuba-Garcia, Pompeyo A.
    Molina-Cabrera, Aura
    Pari-Olarte, Bertha
    Bonifaz-Hernandez, Mario
    Panay-Centeno, Juan F.
    Kong-Chirinos, Jose
    Almeida-Galindo, Jose
    PHARMACIA, 2023, 70 (03) : 603 - 618